Very-Short-Term Sleep Deprivation Slows Early Recovery of Lymphocytes in Septic Patients

Yujing Zhang1,2†, Yuming Wu1,2†, Dan Xu1,2†, Ping Xiao1,2†, Bing Xie1,2, Haiyan Huang1,2, You Shang1,2, Shiying Yuan1,2* and Jiancheng Zhang1,2*

1 Department of Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China, 2 Tongji Medical College, Institute of Anesthesia and Critical Care Medicine, Union Hospital, Huazhong University of Science and Technology, Wuhan, China

Sleep plays an important role in immune function. However, the effects of very-short-term sleep deprivation on the early recovery of immune function after sepsis remain unclear. This study was conducted in the intensive care unit to investigate the effects of 2 consecutive days of sleep deprivation (SD) on lymphocyte recovery over the following few days in septic patients who were recovering from a critical illness. The patients' self-reports of sleep quality was assessed using the Richards–Campbell Sleep Questionnaire at 0 and 24 h after inclusion. The demographic, clinical, laboratory, treatment, and outcome data were collected and compared between the good sleep group and poor sleep group. We found that 2 consecutive days of SD decreased the absolute lymphocyte count (ALC) and ALC recovery at 3 days after SD. Furthermore, post-septic poor sleep decreased the plasma levels of atrial natriuretic peptide (ANP) immediately after 2 consecutive days of SD. The ANP levels at 24 h after inclusion were positively correlated with ALC recovery, the number of CD3+ T cells, or the number of CD3+CD4+ cells in the peripheral blood on day 5 after inclusion. Our data suggested that very-short-term poor sleep quality could slow down lymphocyte recovery over the following few days in septic patients who were recovering from a critical illness. Our results underscore the significance of very-short-term SD on serious negative effects on the immune function. Therefore, it is suggested that continuous SD or several short-term SD with short intervals should be avoided in septic patients.

Keywords: atrial natriuretic peptide, intensive care unit, lymphocytes, RCSQ, short-term sleep deprivation

INTRODUCTION

Sleep and immunologic function are bidirectionally related (1). Sleep is a fundamental physiologic process required for facilitation of the significant restorative processes and plays important roles in the balanced homeostatic regulation of the immune system (1–3). Disturbed sleep and circadian rhythm disruption impair systemic immunological responses including innate and adaptive immune responses and activate inflammation with increased circulating inflammatory cytokines (4–6). Sleep deprivation abrogates the circadian rhythm of the number and function of CD4+ CD25+ natural regulatory T cells and dampens CD4+CD25+ T cell proliferation in the peripheral blood (7). Evidence have shown that sleep plays important roles in fine-tuning the immune system to foster immune defense and help fight infections (8). Sleep rhythm disturbance, shorter sleep...
duration, or poor sleep quality could weaken our body’s defense system and thus render the body more prone to various infections caused by different pathogens, including viruses and bacteria (9–13). Evolutionary increases in mammalian sleep durations are strongly associated with a higher number of circulating immune cells and substantially reduced the levels of parasitic infection (14). Our previous study found that self-reported poor sleep quality during hospitalization in patients with coronavirus disease 2019 (COVID-19) is associated with slow recovery from lymphopenia and prolonged duration of hospital stay (15). Taken together, sleep and the circadian rhythm system exert a strong regulatory influence on immune homeostasis and immune defense.

Sleep disruption is a highly prevalent problem in the intensive care unit (ICU) due to many potential sleep disruptions, including environmental factors (noise, continuous light exposure, frequent patient care activities, mechanical ventilation, medications, etc.) and patient-related factors (underlying illness, the pathophysiology of the acute illness, pain, psychological factors, etc.) (16, 17). Sepsis caused by infection is one of the most common causes of morbidity and mortality in the ICU (18). There are bidirectional crosstalks between infection with sleep impairment (1). Substantial evidence supporting the view that infection per se can lead to sleep disturbances has been accumulated (19–22). Conversely, septic patients or septic mice that underwent frequent sleep disruptions have higher mortality rates (23, 24). Both clinical and animal studies showed that short-term acute sleep loss for up to 2 days could transiently dampen natural killer cell activity in the blood (25–28) and inhibit lymphocyte proliferation (7, 29). However, there are currently no reports of the effects of very-short-term sleep quality on the absolute counts of peripheral blood lymphocytes and the recovery of lymphocytes over the following few days in septic ICU patients. In our study, we aimed to prospectively compare the recovery of lymphocytes and clinical outcomes in septic ICU patients with 2 consecutive days of self-reported good or poor sleep. We focused on the investigation that even very-short sleep deprivation in septic patients could have a significant negative impact on the recovery of immune function over the following few days. The plasma atrial natriuretic peptide (ANP) levels were also detected two times immediately after each day’s sleep assessment to elucidate the possible mechanisms of the effects of short-term sleep deprivation on the recovery of lymphocyte in septic ICU patients.

MATERIALS AND METHODS

Study Design and Participants

For this single-center prospective observational study, 93 septic patients admitted to the integrated ICU of Wuhan Union Hospital between November 1, 2019 and November 30, 2020 were enrolled after meeting the inclusion criteria, which are as follows: (1) patients aged between 18 and 80 years, (2) sequential organ failure assessment (SOFA) score ≥ 2, (3) neurological status allowing communication (alert, oriented, responding to commands), and (4) no visual or hearing impairment. The exclusion criteria included the following: (1) delirium was present during the study period, which was assessed twice daily by trained ICU nurses using the Confusion Assessment Method for the ICU (CAM-ICU), (2) ICU length of stay >30 days at the time of inclusion, (3) acute myocardial infarction or brain natriuretic peptide (BNP) >2,000 pg/ml, (4) alcohol abuse or mental illness, (5) chronic renal failure, (6) chronic insomnia, (7) pregnant or lactating women, and (8) autoimmune disease or hematological malignancy. A total of 81 patients met these criteria and were included in the study (Figure 1).

All invasive mechanically ventilated patients were mainly sedated with propofol with an intravenous pump before and after inclusion when needed.

The study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (permission number: S1164) and registered on the Chinese Clinical Trial Registry (ChiCTR) site (http://www.chictr.org.cn; registration number: ChiCTR1900025497). Informed consent was obtained prior to study enrolment.

Sleep Assessment

At 0 and 24 h after inclusion, self-reported sleep quality was evaluated between 8:00 and 9:00 a.m. using the Richards-Campbell Sleep Questionnaire (RCSQ), a widely used subjective survey instrument in the ICU (30–32). The RCSQ is a validated five-item questionnaire on a 0–100-mm visual analog scale to evaluate perceived sleep depth, sleep latency, number of awakenings, latency after awakenings, and sleep quality. Higher RCSQ scores indicate better sleep quality, and the average value of these five items represent overall sleep quality. Self-reported factors associated with disruptive sleep were also recorded. After the patients’ self-reported sleep assessment, we further checked the patients’ sleep quality by asking the night-shift nurses who completed the RCSQ regarding their patients’ overnight sleep quality.
During the study period, 30 out of the 81 patients included were further excluded as 11 patients with RCSQ scores of 25–75, eight patients with inconsistent sleep assessment at 0 and 24 h after inclusion, six patients with length of ICU stay <48 h after inclusion, three patients with clinical and laboratory data missing, and two patients who received deep sedation (Richmond Agitation–Sedation Scale score during the study period ≤-2). The 51 patients eventually included were divided into two groups according to the RCSQ scores: good sleep group (two RCSQ scores ≥75) and poor sleep group (two RCSQ scores ≤25).

Sleep-Promoting Interventions
At 24 h after inclusion, earplugs and eye masks were used at night to help poor sleep patients sleep better. If the patients in the good sleep group reported poor sleep 24 h after inclusion, earplugs and eye masks were also used at night as a sleep aid. RCSQ was assessed at 48, 72, 96, and 120 h after inclusion.

While earplugs and eye masks were available for clinicians to employ at their clinical discretion, the use of other sleep improvement strategies was not protocolized during the study period.

Data Collection
Basic demographic and clinical data were collected at the time of inclusion: age, sex, body mass index, marital status, education level, comorbidities (cardiovascular and cerebrovascular diseases, endocrine disease, malignancy, chronic respiratory disease, and gastrointestinal disease), length of ICU stay before inclusion (hours), mechanical ventilation time before inclusion (hours), days of analgesia and sedation before inclusion, and treatment (invasive mechanical ventilation, antibiotics, vasoconstrictive agents, immunoregulatory therapy, corticosteroids, immunoglobulin). Data on laboratory parameters [blood routine, blood biochemistry, cardiac biomarkers (troponin I, TnI, and creatine kinase-MB, CK-MB), BNP] were collected at −24, 0, and 24 h after inclusion, which were measured in the laboratory of the Wuhan Union Hospital. The blood routine test (white blood cell count, neutrophil count, lymphocyte count, platelet count, etc.) was performed using BC-3000 auto-hematology analyzer (Mindray, Shenzhen, China). Blood biochemistry (including indices of renal and hepatic functions) was tested using BS-200 automatic biochemical analyzer (Mindray, Shenzhen, China). The level of CK-MB was analyzed using a commercially available kit (eBioscience, An Affymetrix Company, San Diego, CA, USA), and TnI was detected using a TnI assay kit (Cobas, Roche Diagnostics, USA). BNP was determined by CMIA using the ARCHITECT i2000 System and ARCHITECT BNP Reagent Kits (Abbott Laboratories, IL, USA). The plasma ANP levels of the patients were detected by enzyme-linked immunosorbent assay (ELISA) in the laboratory of the Institute of Anesthesia and Critical Care Medicine at 0 and 24 h after inclusion. The Acute Physiology and Chronic Health Evaluation (APACHE) II score and SOFA score were assessed at 0 and 24 h after inclusion. The absolute counts of peripheral blood lymphocytes were recorded on days 3, 4, and 5 after inclusion. All data were checked by two researchers.

Outcomes
The primary outcome was the recovery rate based on absolute lymphocyte count (ALC) on days 3, 4, and 5 after inclusion. The absolute counts of peripheral blood lymphocytes at −24 h after inclusion were set as the baseline value. The formula for the recovery percentage is described as:

\[ \frac{\text{ALC (day 3, day 4 or day 5)} - \text{ALC (baseline)}}{\text{ALC (baseline)}} \times 100\% \]

The secondary outcomes were as follows: (1) ALC on days 3, 4, and 5 after inclusion and (2) total length of ICU stay.

ELISA Detection of ANP
At 0 and 24 h after inclusion, blood samples from each patient were collected and immediately centrifuged at 2,000 g for 15 min, and then the plasma aliquots were separated and stored at −80°C until analyses. Commercial ELISA kits (RayBiotech, Inc., Norcross, GA; Cat#: EIAM-ANP) were used following the kit protocols to determine the plasma ANP levels. After the ELISA procedure has been performed, the microtiter plate is read on an ELISA reader (Elx800, Bio-Tek Instrument Inc., USA) at a wavelength of 450 nm. The results were expressed in pg/ml, taking the given sensitivity values into consideration and calculating from the standard curve.

Flow Cytometry Assay
To measure the lymphocyte subsets, 100 µl of whole peripheral blood was incubated in 900 µl of Tris-NH4Cl potassium lysis buffer (Thermo Fisher Scientific, Waltham, MA) at room temperature for 5 min to lyse the red blood cells. After two times of washing with phosphate-buffered saline, the lymphocyte subsets were measured with a BD Multitest™ 6-color TBNK reagent (BD Biosciences, San Jose, CA) according to the manufacturer's instruction.

Statistical Analysis
Categorical variables were described as number (%). Proportions for categorical variables were compared using the \( \chi^2 \) test, Yates’ continuity corrected \( \chi^2 \) test, or Fisher's exact test. Continuous variables were tested for normal distribution using the Kolmogorov–Smirnov test and Shapiro–Wilk test. Continuous variables were described using mean (SD) if they were normally distributed or median (interquartile range, IQR) if they were not. Continuous variables were compared using independent group \( t \)-tests when the data were normally distributed; otherwise, Mann–Whitney test was used. Correlation was determined by Pearson correlations. A two-sided \( P < 0.05 \) was considered statistically significant. The data collected were all analyzed using SPSS, version 20.0, software (SPSS, Tokyo, Japan).

RESULTS
Patients
Overall, 93 septic patients admitted to the integrated ICU of Wuhan Union Hospital between November 1, 2019 and November 30, 2020 were included in the study. Subsequently, we excluded the following patients: 11 patients with RCSQ scores of 25–75, eight patients with two inconsistent sleep assessment, six patients with length of ICU stay <48 h after
inclusion, three patients with alcohol abuse or mental illness, three patients with chronic renal failure, three patients with clinical and laboratory data missing, two patients with BNP >2,000 pg/ml, two patients who received deep sedation, one patient with acute myocardial infarction, one patient with chronic insomnia, one patient with acute monocytic leukemia, and one patient with granulocytopenia. Therefore, we included 51 patients (27 in the good sleep group and 24 in the poor sleep group) in the final analysis (Figure 1).

Self-Reported Sleep Quality
Patients in the poor sleep group had lower RCSQ scores at the time of inclusion [median, 20 (IQR, 10–23) vs. 80 (IQR, 78–88), P < 0.0001] and 24 h after inclusion [median, 19 (IQR, 14–20) vs. 80 (IQR, 77–90), P < 0.0001] than those in the good sleep group (Table 1). Included among the etiological causes of poor sleep are environmental factors, psychological factors, and discomfort caused by an illness for 83.3, 62.5, and 33.3% of patients, respectively (Table 1).

There were no significant differences in the RCSQ scores between previous poor sleep patients and previous good sleep patients at 48, 72, and 120 h after inclusion (Table 1; all P > 0.05).

Basic Demographic and Clinical Data, Received Treatment at the Time of Inclusion, and Laboratory Parameters at −24, 0, and 24 h After Inclusion
The median age of the patients was 58 years (IQR, 46–68 years), 34% of them were men, and the median body mass index of patients was 23.7 kg/m² (IQR, 20.3–25.7 kg/m²) (Table 2). There were no significant between-group differences in the basic demographic and clinical data as well as the received treatment at the time of inclusion (Table 2). However, the patients in the poor sleep group received longer days of sedation before inclusion (Table 2).

No significant between-group differences were detected in the laboratory parameters at −24, 0, and 24 h after inclusion, including white blood count, neutrophil count, monocyte count, lymphocyte count, platelet count, hemoglobin, total bilirubin, blood urea nitrogen, serum creatinine, creatine kinase-MB, hypersensitive cardiac troponin I, and BNP (Table 3). There was also no significant between-group difference in the APACHE II score and SOFA score at 0 and 24 h after inclusion (Table 3). No significant between-group difference in total length of ICU stay was observed (Table 3).

However, the blood albumin level was significantly lower in the poor sleep group compared to those in the good sleep group at 24 h after inclusion [median, 26.0 g/L (IQR, 25.4–29.3 g/L) vs. 29.4 g/L (IQR, 27.2–32.0 g/L), P = 0.0138], but not at −24 and 0 h after inclusion (Table 3).

Plasma ANP Levels at 0 and 24 h After Inclusion
Patients in the poor sleep group had a decreased plasma level of ANP compared to those in the good sleep group at 24 h after inclusion [median, 31.28 pg/ml (IQR, 15.44–47.49 pg/mL) vs. 45.94 pg/ml (IQR, 36.05–61.54 pg/ml), P = 0.0138], but not at the time of inclusion (P = 0.0775) (Table 3).

The ALC Recovery on Days 3, 4, and 5 After Inclusion
Compared to patients in the good sleep group, patients in the poor sleep group had significantly decreased ALC on day 5 after inclusion [median, 0.62 × 10⁹/L (IQR, 0.39–0.85 × 10⁹/L) vs. 0.87 × 10⁹/L (IQR, 0.72–1.38 × 10⁹/L), P = 0.0017], but not on days 3 and 4 after inclusion (Figure 2).

The recovery rate of ALC was also higher in patients with good sleep than those with poor sleep on day 5 after inclusion [median, 47.4% (IQR, 9.95–105.18%) vs. −25.00% (IQR, −41.79–3.85%), P = 0.0006], but not on days 3 and 4 after inclusion (Figure 2).
Table 2 | Demographics and baseline characteristics of septic patients.

|                           | Total (n = 51) | Good sleep (n = 27) | Poor sleep (n = 24) | P-value |
|---------------------------|---------------|---------------------|--------------------|---------|
| Age, median (IQR), years  | 58 (46–68)    | 60 (44–67)          | 58 (47–69)         | 0.7468  |
| Sex                       |               |                     |                    |         |
| Male                      | 34 (66.7)     | 18 (66.7)           | 16 (66.7)          | >0.9999 |
| Female                    | 17 (33.3)     | 9 (33.3)            | 8 (33.3)           | >0.9999 |
| BMI, median (IQR), kg/m²   | 23.7 (20.3–25.7) | 23.7 (20.7–26.0) | 23.0 (19.2–25.7)  | 0.7187  |
| Marital status            |               |                     |                    |         |
| Married                   | 48 (94.1)     | 26 (96.3)           | 22 (91.7)          | 0.4831  |
| Unmarried                 | 2 (39.2)      | 1 (3.7)             | 1 (4.2)            | 0.5237  |
| Death of a spouse         | 1 (19.6)      | 0 (0)               | 1 (4.2)            | 0.4706  |
| Education level           |               |                     |                    |         |
| ≤ High school             | 48 (94.1)     | 25 (92.6)           | 23 (96.8)          | 0.6235  |
| University or college     | 3 (5.9)       | 2 (7.4)             | 1 (4.2)            | 0.9162  |
| Comorbidities             |               |                     |                    |         |
| Cardiovascular and cerebrovascular diseases | 16 (31.4) | 7 (25.9) | 9 (37.5) | 0.3739 |
| Endocrine disease         | 1 (2.0)       | 0 (0)               | 1 (4.2)            | 0.4706  |
| Malignancy                | 5 (9.8)       | 1 (3.7)             | 4 (16.7)           | 0.2792  |
| Chronic respiratory disease | 4 (7.8) | 2 (7.4) | 2 (8.3) | 0.6899 |
| Gastrointestinal disease  | 7 (13.7)      | 4 (14.8)            | 3 (12.5)           | 0.8667  |
| Length of ICU stay before inclusion (hours) | 111 (47–216) | 72 (48–216) | 120 (31–251) | 0.9292 |
| Mechanical ventilation time before inclusion (hours) | 48 (0–158) | 48 (0–144) | 58 (0–297) | 0.4628 |
| Days of sedation before inclusion (days) | 2.0 (1.0–5.0) | 1.0 (0.0–3.0) | 4.5 (1.0–7.0) | 0.0029*|
| Days of analgesia before inclusion (days) | 3.0 (1.0–5.0) | 2.0 (0.0–6.0) | 4.0 (1.0–6.0) | 0.2190 |
| Treatment at inclusion    |               |                     |                    |         |
| Invasive mechanical ventilation | 16 (31.4) | 7 (25.9) | 9 (37.5) | 0.3739 |
| Antibiotics               | 51 (100)      | 27 (100)            | 24 (100)           | –       |
| Vasocostrictive agents    | 5 (9.8)       | 1 (3.7)             | 4 (16.7)           | 0.2792  |
| Immunoregulatory therapy  | 0 (0)         | 0 (0)               | 0 (0)              | –       |
| Corticosteroids           | 0 (0)         | 0 (0)               | 0 (0)              | –       |
| Immunoglobulin            | 0 (0)         | 0 (0)               | 0 (0)              | –       |

Values are numbers (percentages) unless stated otherwise. IQR, interquartile range; n, number. P-values indicate differences between good-sleep and poor-sleep patients. *P < 0.05 was considered statistically significant.

Correlation Coefficient Analysis of Plasma ANP Levels With ALC, ALC Recovery, or Lymphocyte Subsets in the Peripheral Blood

The septic patients with poor sleep had a lower number of CD3+ T-lymphocytes, CD3+ CD4+ T-lymphocytes, CD3+ CD8+ T-lymphocytes, and CD3-CD16+ CD56+ natural killer (NK) cells in the peripheral blood compared to septic patients with good sleep on day 5 after inclusion (Figure 3).

In all patients, correlation coefficient analysis showed a positive correlation between plasma ANP levels at 24 h after inclusion and ALC recovery on day 5 after inclusion (r = 0.394, P = 0.018) (Table 4). The plasma ANP levels at 24 h after inclusion also showed a positive correlation with ALC recovery on day 5 after inclusion among the patients with good sleep (r = 0.470, P = 0.027) or the patients with poor sleep (r = 0.527, P = 0.044) (Table 4).

An analysis of the correlation between plasma ANP levels at 24 h after inclusion and ALC on day 5 after inclusion did not show any correlation (all P > 0.05; Table 4). However, there were positive correlations between plasma ANP levels at 24 h after inclusion and the number of CD3+ T-lymphocytes (r = 0.391, P = 0.006) or the number of CD3+ CD4+ T-lymphocytes (r = 0.527, P < 0.001) in the peripheral blood on day 5 after inclusion (Figure 4).

Discussion

Patients with sepsis caused by pathogenic infections, including bacteria and viruses, typically present lymphopenia (15, 33–36), which can serve as a biomarker for immunosuppression (37, 38). In addition, a continuous and sustained decrease in total circulating lymphocytes is closely associated with disease aggravation and death in septic patients (33, 39). Through prospectively comparing the effects of very-short-term self-reported good or poor sleep on ALC and the recovery rate of ALC over the subsequent 1–3 days, we found that 2 consecutive days of poor sleep decreased ALC and dampened ALC recovery on day...
### TABLE 3 | Laboratory parameters at −24, 0 and 24 h after inclusion, and total length of ICU stay.

|                  | Normal range   | Hours after inclusion | Total (n = 51) | Good-sleep (n = 27) | Poor-sleep (n = 24) | P-value |
|------------------|----------------|----------------------|---------------|---------------------|---------------------|---------|
| **Blood routine** |                |  |                |                    |                     |         |
| White blood count, $\times 10^9$/L | 3.50–9.50     | −24 | 10.53 ± 5.19   | 10.41 ± 5.06    | 10.66 ± 5.44       | 0.8672  |
| Neutrophil count, $\times 10^9$/L   | 1.80–6.30     | −24 | 7.71 (5.70–11.52) | 7.86 (4.94–9.93) | 7.08 (6.14–11.94) | 0.8169  |
| Monocyte count, $\times 10^9$/L     | 0.10–0.60     | −24 | 0.50 (0.36–0.81) | 0.59 (0.36–0.87) | 0.47 (0.36–0.60)  | 0.5526  |
| Lymphocyte count, $\times 10^9$/L   | 1.10–3.20     | −24 | 0.78 (0.52–1.15) | 0.80 (0.41–0.95) | 0.73 (0.53–1.36)  | 0.8363  |
| Platelet count, $\times 10^9$/L     | 125–350       | −24 | 154 (67–224)   | 160 (88–246)    | 154 (139–214)      | 0.5712  |
| **Blood biochemistry** |                |  |                |                    |                     |         |
| Albumin, g/L   | 33.0–55.0      | −24 | 27.9 (26.2–31.3) | 28.0 (26.2–32.3) | 27.4 (25.4–30.7)  | 0.8260  |
| Total bilirubin, µmol/L | 3.0–20.0      | −24 | 15.9 (8.7–28.4) | 17.6 (7.8–34.0) | 15.4 (8.9–27.7)  | 0.9674  |
| Blood urea nitrogen, mmol/L | 2.90–8.20     | −24 | 7.32 (5.07–12.43) | 8.83 (4.19–12.60) | 7.91 (5.50–11.16) | 0.6009  |
| Serum creatinine, µmol/L | 57.0–111.0    | −24 | 55.1 (41.7–90.3) | 59.4 (46.3–102.6) | 52.2 (34.8–93.6) | 0.0158  |
| Hypersensitive cardiac troponin I $\geq$ 26.2, ng/L | <26.2 | −24 | 3 (5.9) | 1 (3.7) | 2 (8.3) | 0.9162 |
| Cardiac biomarkers† |                |  |                |                    |                     |         |
| Creatine kinase-MB $\geq$ 6.6, ng/mL | <6.6 | −24 | 0 | 4 (7.8) | 2 (3.5) | 2 (8.3) | 0.6899 |
| Hypersensitive cardiac troponin I $\geq$ 26.2, ng/L | <26.2 | −24 | 0 | 10 (19.8) | 5 (18.5) | 5 (20.8) | 0.8354 |
| BNP†, pg/mL | <100 | −24 | 227.5 (91.5–513.7) | 227.5 (55.7–407.2) | 235.9 (93.4–869.8) | 0.5102 |
| ANP, pg/mL | <500 | −24 | 31.03 (23.43–50.09) | 37.30 (25.69–82.83) | 26.41 (17.84–40.46) | 0.0775 |
| APACHE II score |                |  | 11 (9–13) | 10 (8–12) | 13 (9–14) | 0.0691 |
| SOFA score |                |  | 11 (7–13) | 11 (6–13) | 11 (6–14) | 0.2559 |
| Total length of ICU stay, median (IQR), d |                |  | 9.0 (4.0–15.0) | 9.0 (4.0–16.0) | 8.5 (6.0–15.0) | 0.7108 |

Values are mean ± standard deviation (SD), median [IQR [range]] or numbers (percentages). APACHE II, acute physiology and chronic health evaluation II; IQR, interquartile range; n, number; SOFA, sequential organ failure assessment. *P-values indicate differences between good-sleep and poor-sleep patients. †P < 0.05 was considered statistically significant.

†Data regarding cardiac biomarkers at 24 h prior to inclusion were missing for 12 patients (44.4%) in the good-sleep group, and 13 patients (54.2%) in the poor-sleep group.
‡Data were missing for the measurement of BNP at 24 h prior to inclusion in 10 patients (37.0%) in the good-sleep group, and eight patients (33.3%) in the poor-sleep group.
§The plasma ANP levels of seven healthy adult volunteers were 0.64 pg/mL (IQR, 0.60–3.69 pg/mL).
5 after inclusion. Interestingly, there is a decreasing tendency for these two parameters on days 3 and 4 in septic patients with 2 consecutive days of poor sleep compared to septic patients with good sleep. Our data indicated that very-short-term poor sleep could worsen post-septic immunosuppression as demonstrated by a significant difference in ALC on day 5 between the two groups, although the sleep quality of the patients in the poor sleep group was improved in the following three nights. Furthermore, our previous study found that recovery rate based on ALC after sepsis could also reflect recovery from lymphopenia; 2–3 weeks of self-reported poor sleep quality during hospitalization in COVID-19 patients with lymphopenia was associated with a slow recovery of ALC (15). In our present study, very-short-term poor sleep in septic patients could slow down ALC recovery on day 3 after 2 consecutive days of poor sleep, which indicated that very-short-term poor sleep could not only decrease ALC but could also dampen ALC recovery on day 3 after 2 consecutive days of poor sleep in septic ICU patients. Our results suggest that sleep deprivation, even very-short-term sleep deprivation, could exert important detrimental effects on the recovery rate of post-septic immunosuppression. However, the reason why there was a delay between the 2 consecutive days of poor sleep and decreased ALC or slower ALC recovery is unclear, which may be because the immune function needs a certain amount of time to be suppressed. The sepsis-induced immunosuppression peaks several days after sepsis; immunostimulation therapy could promote the recovery of immune function and improve sepsis mortality (40, 41). Interestingly, the poor sleep patients had lower blood albumin levels compared to the good sleep patients, suggesting that the relatively lower levels of blood albumin in poor sleep patients may affect subsequent ALC recovery to some extent due to the potential immunomodulatory and anti-inflammatory effects of albumin in critically ill patients (42–44). Therapeutic preparations of human albumin are shown to be able to promote the major histocompatibility complex class II-restricted activation of antigen-specific T cells (43). Albumin preconditioning could abrogate the lipopolysaccharides (LPS)-mediated increase in the protein levels of tumor necrosis factor alpha (TNF-α) in cultured macrophages and septic mice (44). Due to the negative correlation between hyperinflammation and systemic immune function (38, 45, 46), hyperinflammation mediated by reduced levels of albumin in the poor sleep group would also compromise the immune function.

ANP, a cardiovascular hormone mainly secreted by the heart atria (47), plays important protective roles in many diseases, including ventricular hypertrophy, myocardial injury, atherosclerosis, hypertension, tumor, acute lung injury, ischemia/reperfusion injury, and sepsis (48, 49). ANP has immunomodulatory capacity to stimulate the differentiation of naive CD4+ cells toward the T helper (Th) 2 and/or Th17 phenotype (48). In addition to regulating adaptive immunity, ANP is also involved in innate immunity, being able to stimulate macrophage phagocytosis, promote reactive oxygen species release, increase NK cytotoxicity, inhibit the synthesis and release of proinflammatory mediators (TNF-α, interleukin-1, monocyte chemoattractant protein 1, nitric oxide, cyclooxygenase-2, etc.), and reduce the expression of adhesion molecules (vascular cell adhesion molecules, intercellular cell adhesion molecule-1, E-selectin, etc.) (48, 50–53). The anti-inflammatory and immunomodulatory effects of ANP may be through the activation of guanylyl cyclase-coupled receptor A (GC-A)/cyclic guanosine monophosphate (cGMP) signaling in dendritic cells (48). In an experimental model of sepsis, pretreatment of mice with ANP resulted in improved survival of mice after LPS challenge (54), which may be due to the potent inhibitory effect of ANP on LPS and TNF-α-induced increase in endothelial cell permeability (49). One previous study showed that chronic sleep deprivation for 1 month could abrogate an exercise-induced increase in the plasma levels of ANP, without obvious effects on the plasma levels of BNP (55). Consistently, in our present study, we found that 2 consecutive days of poor sleep could markedly decreased the plasma ANP levels, without significant effects on plasma BNP levels. Surprisingly, the plasma ANP levels at 24 h after inclusion were significantly positively correlated to ALC recovery on day 5 after inclusion, indicating that ANP might play important roles in sleep-mediated immunoregulation. The promoting effects of ANP on the early recovery of immune function may be due to its anti-inflammatory effects (48–54, 56) because hyperinflammation is negatively associated with systemic immune function (38, 45, 46). In addition, ANP can also affect the adaptive immunity, being able to stimulate the differentiation of naive CD4+ cells (48) and promote dendritic cell-mediated T cell polarization (57) mediated by its principal

![FIGURE 2](image-url)
receptor GC-A, which is highly expressed in thymus (58) and immune cells (including macrophages, dendritic cells, and T lymphocytes) (59). Our data also indicated that the plasma level of ANP could be used as a predictor of recovery of immune function in septic patients. However, no significant correlation between the plasma ANP levels at 24 h after inclusion and

TABLE 4 | Correlation coefficient analysis of plasma ANP levels at 24 h after inclusion with ALC on day 5 after inclusion and recovery of ALC on day 5 after inclusion.

|                      | ALC on day 5 after inclusion | Recovery of ALC on day 5 after inclusion |
|----------------------|-----------------------------|----------------------------------------|
|                      | Total | Good-sleep | Poor-sleep | Total | Good-sleep | Poor-sleep |
| Plasma ANP levels at 24 h after inclusion | $r = 0.192$ | $r = 0.130$ | $r = 0.168$ | $r = 0.394^*$ | $r = 0.470^*$ | $r = 0.527^*$ |
|                      | $P = 0.262$ | $P = 0.565$ | $P = 0.567$ | $P = 0.018$ | $P = 0.027$ | $P = 0.044$ |

ALC, absolute lymphocyte count; ANP, atrial natriuretic peptide. *$P < 0.05$ was considered statistically significant.
FIGURE 4 | Correlation analysis of the plasma levels of atrial natriuretic peptide (ANP) with lymphocyte subsets in the peripheral blood. The plasma levels of ANP at 24 h after inclusion were positively correlated with the number of CD3+ T-lymphocytes \( (r = 0.391, P = 0.006) \) (A) or the number of CD3+ CD4+ T-lymphocytes \( (r = 0.527, P < 0.001) \) (B) on day 5 after inclusion. No significant correlations between the plasma levels of ANP at 24 h after inclusion with the number of CD3+ CD8+ T-lymphocytes (C), the number of CD3− CD16+ CD56+ natural killer cells (D), or the number of CD19+ B-lymphocytes (E) on day 5 after inclusion were detected.

ALC on day 5 after inclusion was observed in our study, which remains unknown.

The RCSQ, a potential practical and valid instrument with feasibility and low cost, has been the most widely used subjective survey instrument for measuring the sleep quality of ICU patients (30–32). In a clinical study of 70 ICU patients, the RCSQ had been validated against polysomnography (32), which is considered as the gold-standard method for evaluating sleep. We lowered the upper limit of the RCSQ score that defines poor sleep quality (≤25) to minimize bias, while the cutoff point differentiating good and poor sleep was 70/100 in previous studies (60, 61). In addition, after the patients’ self-reported sleep assessment, we further checked by asking the night-shift nurses who completed the RCSQ regarding their patients' overnight sleep quality to minimize the recollection and response bias caused by subjective assessment. Nurses may overestimate the patients’ perceived sleep quality on the RCSQ compared with their patients (62); thus, we used patient–nurse interraters to ensure the patients’ poor sleep. Because the appropriateness of the patients’ self-reported sleep quality as assessed by RCSQ would be compromised if they are sedated and/or delirious, the patients with deep sedation or delirium during the study period were excluded in our study.

In the included patients with sepsis, the most important etiological causes of poor sleep were environmental and psychological factors, which accounted for 83.3 and 62.5%, respectively. Another major factor that contributed to the patients’ poor sleep is physical discomfort caused by an illness. These factors are the major causal factors of sleep disturbance in ICU patients and could negatively affect their recovery from a critical illness (63–67). Therefore, improving the ward environment (reducing the light and noise levels at night, segregating patients from each other by curtains, using earplugs or eye masks, etc.), psychological therapy [social support intervention, spiritual encouragement, psychological comfort, emotional support, relaxation intervention plus relaxing music (muscle relaxation, mental imagery, audiotape), psychotropic drug therapy, etc.], and alleviating psychological comfort (adequate analgesia, proper sedation, optimizing ventilator mode or type, etc.) are essential to improve the sleep quality of septic patients in ICU wards (68). Furthermore, we found that the patients with poor sleep received longer days of sedation before inclusion, indicating that long-term sedation may be associated with poor sleep afterwards. In our study, the invasive mechanically ventilated patients were primarily sedated with propofol before and after inclusion. Propofol has been shown to have a negative immunomodulatory effect (69–72); it can decrease T-cell proliferation and IL-2 production (71). Therefore, patients with poor sleep in our study had a longer period of sedation before inclusion,
which may also lead to a subsequent slower recovery of immune function. There were some notable limitations in our study. First, it was a single-center study with a small sample size. Future prospective studies with large patient cohorts are needed to validate the results. Second, although multiple criteria for grouping based on the RCSQ were strictly defined in this study, there could still be a recollection and response bias. Therefore, objective sleep monitoring is needed in future studies. Third, bidirectional causality might exist between poor sleep quality and the recovery of immune function in septic patients. We cannot rule out the possibility that the underlying more severe condition caused the poor sleep quality in septic patients, although no significant between-group differences in the APACHE II score and SOFA score as well as laboratory parameters were detected within 24h of inclusion. Fourth, the sleep quality in the ICU before inclusion could not be assessed due to the sepsis-induced brain dysfunction and administration of deep sedation. Whether possible differences in circadian rhythm changes before inclusion between the two groups could have an impact on the subsequent recovery of immune function after sepsis is unclear. Fifth, a relatively small group of ICU patients who were awake and able to communicate were included in our study; thus, selecting only a subgroup of less severely ill patients could make it difficult to generalize our findings to the whole ICU population. Although sleep quality assessment in patients with sedation and/or delirium remains difficult, interventions aimed at improving sleep quality may also have beneficial effects. Sixth, the long-term impact of very-short-term sleep deprivation on patient outcomes was not taken into account. The very-short-term sleep deprivation may exert long-term negative consequences in the recovery of immune function in septic patients.

In conclusion, in septic patients who were recovering from critical illness, very-short-term poor sleep quality was associated with a slow recovery of lymphocytes over the following few days, and the plasma levels of ANP were positively correlated with the subsequent recovery of lymphocytes. Therefore, continuous sleep deprivation or several short-term sleep deprivations with short intervals may continually worsen the recovery of immune function during recovery from critical illness. Poor recovery of immune function could negatively affect the prognosis of septic patients (33, 39). Attention should be paid to the patient’s sleep quality every day. It is important to adopt comprehensive treatment measures during hospitalization to improve the sleep quality of septic patients to promote the recovery of immune function.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The study was approved by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Permission number: S1164). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JZ and SY had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis and contributed to the concept and design. JZ, YZ, YW, DX, PX, BX, and HH contributed to the acquisition, analysis, or interpretation of data. JZ contributed to the drafting of the manuscript and the statistical analysis. SY contributed to the critical revision of the manuscript for important intellectual content and supervised the study. YS and SY provided administrative, technical, or material support. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank all the patients and their families as well as the doctors in charge and nurses who were involved in the study.

REFERENCES

1. Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease. Physiol Rev. (2019) 99:1325–80. doi: 10.1152/physrev.00010.2018

2. Haspel JA, Anafi R, Brown MK, Cermakian N, Depner C, Desplats P, et al. Perfect timing: circadian rhythms, sleep, and immunity - an NIH workshop summary. JCI Insight. (2020) 5:e131487. doi: 10.1172/jci.insight.131487

3. Mukherjee S, Patel SR, Kales SN, Ayas NT, Strohl KP, Gozal D, et al. An official american thoracic society statement: the importance of healthy sleep. Recommendations and future priorities. Am J Respir Crit Care Med. (2015) 191:1450–8. doi: 10.1164/rccm.201504-0767ST

4. Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. (2015) 66:143–72. doi: 10.1146/annurev-psych-012013-115205

5. Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep. (2007) 30:1145–52. doi: 10.1093/sleep/30.9.1145

6. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab. (2004) 89:2119–26. doi: 10.1210/jc.2003-031562

7. Bollinger T, Bollinger A, Skrums L, Dimitrov S, Lange T, Solbach W. Sleep-dependent activity of T cells and regulatory T cells. Clin Exp Immunol. (2009) 155:231–8. doi: 10.1111/j.1365-2249.2008.03822.x

8. Toth LA, Krueger JM. Alteration of sleep in rabbits by Staphylococcus aureus infection. Infect Immun. (1988) 56:1785–91. doi: 10.1128/IAI.56.7.1785-1791.1988

9. Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RR. Sleep habits and susceptibility to the common cold. Arch Intern Med. (2009) 169:662–7. doi: 10.1001/archinternmed.2008.505

10. Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally assessed sleep and susceptibility to the common cold. Sleep. (2015) 38:1353–9. doi: 10.5663/sleep.4968
30. Nagatomi K, Masuyama T, Iizuka Y, Makino J, Shiotsuka J, Suzuki M.
27. Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night
26. Irwin M, Mascovich A, Gillin JC, Willoughby R, Pike J, Smith TL.
29. Wilder-Smith A, Mustafa FB, Earnest A, Gen L, Macary PA. Impact of
25. Fondell E, Axelsson J, Franck K, Ploner A, Lekander M, Balter K, et al. Short
22. Sharpley AL, Cooper CM, Williams C, Godlewska BR, Cowen PJ. Effects
18. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock.
17. Pisani MA, Friese RS, Gehlbach BK, Schwab RJ, Weinhouse GL, Jones SF.
19. Krueger JM, Majde JA. Cytokines and sleep.
16:1. doi: 10.1186/s40560-020-0433-x
8:16. doi: 10.1186/s40560-018-0433-x
10:125–37. doi: 10.1080/17512433.2018.1412827
10:109. doi: 10.1159/000236827
16:97–100. doi: 10.1195/000236827
56:493–8. doi: 10.1097/00006842-199411000-00004
3:23–429–35. doi: 10.1007/000213-016-4381-x
37:1077–86. doi: 10.1186/sleep.3764
1:72–17. doi: 10.1186/s13054-018-2182-y
9:7. doi: 10.1186/1471-2418-9-7
13:260–8. doi: 10.1097/S1417-01218-00004
5:932–41. doi: 10.1189/jlb.0603254
74:932–41. doi: 10.1189/jlb.0603254
318:190c3a1
75:1367–75. doi: 10.1195/00075198-2019-000004
36:97–100. doi: 10.1016/j.jaci.2005.08.005
56:943–8. doi: 10.1111/j.1211-2127
395:1054–62. doi: 10.1016/S0167-0115(01)00218-X
99:21–9. doi: 10.1016/S0167-0115(01)00218-X
79:56–62. doi: 10.1016/j.mvr.2009.
135:1–13. doi: 10.1111/j.1423-4041.2011.01475.x
505:1367–75. doi: 10.1186/00075198-2019-000004
1365:486–99. doi: 10.1093/nr/38688
1:125–37. doi: 10.1080/17512433.2018.1412827
8:109. doi: 10.1159/000236827
109:21–9. doi: 10.1016/S0167-0115(01)00218-X
395:497–506. doi: 10.1016/j.jimmunol.2020.03.066-3
79:56–62. doi: 10.1016/j.mvr.2009.
36:175–81. doi: 10.1038/nri3862
78:109. doi: 10.1159/000347210
376:97–100. doi: 10.1016/j.jimmunol.2020.03.066-3
75:1367–75. doi: 10.1195/00075198-2019-000004
13:260–8. doi: 10.1097/S1417-01218-00004
15:486–99. doi: 10.1093/nr/38688
10:1118-9. doi: 10.1097/00006842-199411000-00004
36:175–81. doi: 10.1038/nri3862
29:27–99–1000.e3. doi: 10.1016/j.chom.2020.04.009
5:21–9. doi: 10.1016/S0167-0115(01)00218-X
101:131–13. doi: 10.1111/j.1423-4041.2011.01475.x
63:125–37. doi: 10.1080/17512433.2018.1412827
43:1–13. doi: 10.1111/j.1423-4041.2011.01475.x
8:109. doi: 10.1159/000347210
395:1054–62. doi: 10.1016/S0167-0115(01)00218-X
15:486–99. doi: 10.1093/nr/38688
10:1118-9. doi: 10.1097/00006842-199411000-00004
75:1367–75. doi: 10.1195/00075198-2019-000004
13:260–8. doi: 10.1097/S1417-01218-00004
15:486–99. doi: 10.1093/nr/38688
10:1118-9. doi: 10.1097/00006842-199411000-00004
75:1367–75. doi: 10.1195/00075198-2019-000004
13:260–8. doi: 10.1097/S1417-01218-00004
13:260–8. doi: 10.1097/S1417-01218-00004
13:260–8. doi: 10.1097/S1417-01218-00004
53. Kiemper AK, Vollmar AM. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem. (1998) 273:13444–51. doi: 10.1074/jbc.273.22.13444

54. Ladetzki-Baehs K, Keller M, Kiemper AK, Koch E, Zahler S, Wendel A, et al. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology. (2007) 148:332–6. doi: 10.1210/en.2006-0935

55. Tanabe K, Yamamoto A, Suzuki N, Akashi Y, Seki A, Samejima H, et al. Atrial natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide. Endocrinology. (1996) 137:1706–13. doi: 10.1210/endo.137.5.8612505

56. Mohapatra SS, Lockey RF, Vesely DL, Gower WR Jr. Natriuretic peptides and genesis of asthma: an emerging paradigm? J Allergy Clin Immunol. (2004) 114:520–6. doi: 10.1016/j.jaci.2004.05.028

57. Minnion H, Molloy DW, O’Caoimh R. Sleep disturbance in older patients in the emergency department: prevalence, predictors and associated outcomes. Int J Environ Res Public Health. (2019) 16:3577. doi: 10.3390/ijerph16193577

58. McKinley S, Fien M, Elliott R, Elliott D. Sleep and psychological health during early recovery from critical illness: an observational study. J Psychosom Res. (2013) 75:539–45. doi: 10.1016/j.jpsychores.2013.09.007

59. Kiemper AK, Vollmar AM. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem. (1998) 273:13444–51. doi: 10.1074/jbc.273.22.13444

60. Ladetzki-Baehs K, Keller M, Kiemper AK, Koch E, Zahler S, Wendel A, et al. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology. (2007) 148:332–6. doi: 10.1210/en.2006-0935

61. McKinley S, Fien M, Elliott R, Elliott D. Sleep and psychological health during early recovery from critical illness: an observational study. J Psychosom Res. (2013) 75:539–45. doi: 10.1016/j.jpsychores.2013.09.007

62. Kamdar BB, Shah PA, King LM, Kho ME, Zhou X, Colantuoni E, et al. Patient-nurse interrater reliability and agreement of the Richards-Campbell sleep questionnaire. Am J Crit Care. (2012) 21:261–9. doi: 10.4037/ajcc2011

63. Delaney LJ, Van Haren F, Lopez V. Sleeping on a problem: the impact of sleep disturbance on intensive care patients - a clinical review. Ann Intensive Care. (2015) 5:3. doi: 10.1186/s13613-015-0043-2

64. Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter A, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. (2018) 46:e825–73. doi: 10.1097/CCM.0000000000003259

65. Pulak LM, Jensen L. Sleep in the intensive care unit: a review. J Intensive Care Med. (2016) 31:14–23. doi: 10.1177/0885066614538749

66. Kamdar BB, Needham DM, Collop NA. Sleep deprivation in critical illness: its role in physical and psychological recovery. J Intensive Care Med. (2012) 27:97–111. doi: 10.1177/088506661094322

67. Friese RS. Sleep and recovery from critical illness and injury: a review of theory, current practice, and future directions. Crit Care Med. (2008) 36:697–705. doi: 10.1097/CCM.0B013E3181643F29

68. Hu RF, Jiang XY, Chen J, Zeng Z, Chen XY, Li Y, et al. Non-pharmacological interventions for sleep promotion in the intensive care unit. Cochrane Database Syst Rev. (2015) 2015:D8808. doi: 10.1002/14651858.CD008808.pub2

69. Visvabharathy L, Freitag NE. Propofol sedation exacerbates kidney pathology and dissemination of bacteria during Staphylococcus aureus bloodstream infections. Infect Immun. (2017) 85:e00997–17. doi: 10.1128/IAI.00997-17

70. Chen MS, Lin WC, Yeh HT, Hu CL, Sheu SM. Propofol specifically suppresses IL-1β secretion but increases bacterial survival in Staphylococcus aureus-infected RAW264.7 cells. Mol Cell Biochem. (2018) 449:117–25. doi: 10.1007/s11010-018-3348-2

71. Yuki K, Soriano SG, Shimaoka M. Sedative drug modulates T-cell and lymphocyte function-associated antigen-1 function. Anesth Analg. (2011) 112:830–8. doi: 10.1213/ANE.0b013e31820dcabb

72. Visvabharathy L, Xayarath B, Weinberg G, Shilling RA, Freitag NE. Propofol increases host susceptibility to microbial infection by reducing subpopulations of mature immune effector cells at sites of infection. PLoS ONE. (2015) 10:e0138043. doi: 10.1371/journal.pone.0138043

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Wu, Xu, Xiao, Xie, Huang, Shang, Yuan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.